Clinical Trial

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 7, 2024 (before its estimated May 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma
Trial Details
NCT Number NCT06298266
Lead Sponsor Guangdong Second Provincial General Hospital
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 15 participants
Start Date 2024-03-29
Primary Completion 2026-05-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-07